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Abstract
Background & Aims: Advances in direct- acting antiviral treatment of HCV have rein-
vigorated public health initiatives aimed at identifying affected individuals. We evalu-
ated the possible impact of only diagnosed and linked- to- care individuals on overall 
HCV burden estimates and identified a possible strategy to achieve the WHO targets 
by 2030.
Methods: Using a modelling approach grounded in Italian real- life data of diagnosed 
and treated patients, different linkage- to- care scenarios were built to evaluate poten-
tial strategies in achieving the HCV elimination goals.
Results: Under the 40% linked- to- care scenario, viraemic burden would decline 
(60%); however, eligible patients to treat will be depleted by 2025. Increased case 
finding through a targeted screening strategy in 1948- 1978 birth cohorts could 
supplement the pool of diagnosed patients by finding 75% of F0- F3 cases. Under 
the 60% linked- to- care scenario, viraemic infections would decline by 70% by 
2030 but the patients eligible for treatment will run out by 2028. If treatment is to 
be maintained, a screening strategy focusing on 1958- 1978 birth cohorts could 
capture 55% of F0- F3 individuals. Under the 80% linked- to- care scenario, screen-
ing limited in 1968- 1978 birth cohorts could sustain treatment at levels required to 
achieve the HCV elimination goals.
Conclusion: In Italy, which is an HCV endemic country, the eligible pool of patients to 
treat will run out between 2025 and 2028. To maintain the treatment rate and achieve 
the HCV elimination goals, increased case finding in targeted, high prevalence groups 
is required.
K E Y W O R D S
chronic infection, HCV, linkage to care, WHO
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1  | INTRODUC TION
Hepatitis C virus (HCV) is a leading cause of liver- related morbid-
ity and mortality worldwide. An estimated 71 million people are 
affected by chronic hepatitis C (CHC) infection1 and a significant 
number of those chronically infected progress to cirrhosis or liver 
cancer if left untreated.2,3 However, the development of direct- 
acting antiviral (DAA) therapy has revolutionized the approach 
to treatment and reinvigorated public health initiatives aimed at 
identifying patients with CHC. Galvanized by these results, the 
World Health Organization (WHO) foresees the elimination of 
HCV infection by 2030 through achieving the Global Health Sector 
Strategy Goals (GHSS) for Hepatitis.4 While targeted screening 
programmes for high- risk populations such as injection drug users 
are necessary for elimination of Hepatitis C,5,6 little has been done 
to understand what increases in diagnosis and treatment are nec-
essary in the general population of high endemic countries for 
achieving these goals. Given that the use of DAAs regardless of 
fibrosis stage is cost- effective,7 it is crucial that health policies ex-
pand treatment access for all HCV- infected individuals. The goal 
of this study was to use a new modelling approach, grounded in 
real- life cohort data of diagnosed and treated patients, to compare 
different linkage to care scenarios to the overall HCV- infected 
population in Italy. We aimed to evaluate the possible impact of 
only linked- to- care individuals on overall HCV burden and to iden-
tify a possible strategy to achieve the WHO targets by 2030.
2  | METHODS
2.1 | Study design
Two Markov- disease burden models were developed to assess the 
current and future HCV disease burden in Italy. The “Italy Polaris” 
model is grounded in the natural history of HCV progression and 
forecasts the HCV impact on the general population. A similar HCV 
disease burden model, grounded in the current distribution of linked- 
to- care patients of the PITER (Italian Platform for the Study of Viral 
Hepatitis Therapies) cohort was also developed.8
2.1.1 | PITER cohort
PITER is an ongoing cohort of 9145 (at time of study) consecutively 
enroled patients from 90 public, general hospitals and university 
medical centres distributed across Italy. The PITER cohort is con-
sidered a representative sample of linked- to- care patients with no 
treatment access restrictions on the basis of healthcare system 
reimbursement criteria.8 PITER aims to evaluate the expected 
impact of DAAs on the natural course of hepatitis infection and 
on long- term morbidity and mortality in a real- life setting in Italy. 
The PITER inclusion criteria are: all HCV- infected patients (any 
stage, any genotype, including HBV, HDV, or HIV co- infection) 
at least 18 years of age consecutively referred to outpatient clin-
ics of the participating clinical centres during enrolment phases, 
who are untreated at the time of enrolment. The mean age of en-
rolled patients is 61 (range 18- 94) years of age and the ratio of 
males to female is 1/1.2 (55% male).8 The older age of patients 
enrolled in PITER represents the cohort effect of HCV infection in 
Italy. Of patients enrolled in the PITER cohort in 2016, 52% were 
F0- F3, 38% F4 and 10% had decompensated cirrhosis or HCC.8 
Treatment initiations occurring among enrolled patients cover the 
full evolution of DAA access in Italy from 2014 on.
2.1.2 | AIFA treatment data
Real- life reported treatment data were provided from January 
2015 through August 2017 by the Italian Medicines Agency (AIFA).9 
AIFA reimbursement criteria included fibrosis stage ≥F3 patients, 
patients with extrahepatic manifestations in any stage of fibrosis 
and liver transplant recipients, until the end of 2016. Beginning in 
2017, treatment was expanded to all patients independent of fi-
brosis score.9
2.1.3 | Italy Polaris and PITER adjusted models
For this analysis, two separate models were constructed. First, a 
Markov HCV disease progression model (the “Italy Polaris model”) 
was built using previously described methodology10 to forecast the 
annual prevalence of chronic HCV infection in Italy by liver disease 
stage, sex and age. In this model, the number of annual historical HCV 
incident cases, starting in 1950, and their sex and age group distribu-
tion was back- calculated to match the modelled prevalence by sex 
and age group in 2015 to reported estimates11 (Section 1 in Appendix 
S1). The reported number of annual treated patients as tracked in the 
AIFA Monitoring Registry for DAAs9 was allocated to the age and 
liver disease stage of the eligible HCV- infected population by the 
relative size of population in each treatment- eligible disease stage 
Key Points
• In Italy, the eligible pool of chronic HCV infected pa-
tients to treat will run out between 2025-2028, leaving 
a significant proportion of infected individuals undiag-
nosed and without access to care.
• Increased case finding in high prevalent birth cohorts of 
the general population through targeted screening 
strategies are necessary to achieve the WHO goals for 
elimination of viral hepatitis.
• If the treatment rate decreases before 2025, increased 
case finding in individuals born between 1948-1978 is 
necessary to achieve the WHO elimination goals. If the 
treatment rate is sustained until 2028, screening strate-
gies focusing on individuals born between 1958-1978 
are warranted.
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(Table 1). The number of annual treatments initiated within each dis-
ease stage was uniformly distributed across treatment- eligible ages.
Afterwards, the Italy Polaris model was adapted to initiate the 
model in 2015 (the “PITER adjusted model”) with the disease stage, 
sex and age group distribution of linked- to- care prevalent cases as 
reported in PITER (Section 2 in Appendix S1). Background mortal-
ity by 5- year age and sex cohort, standard mortality ratios and the 
future incident cases were applied as in the Italy Polaris model. The 
number of annual treatments initiated in this model was the real- 
life number of treatments with DAAs from 2015 to August 2017 by 
disease stage and age as provided by the AIFA Monitoring Registry.9
2.2 | Statistical analysis
Two general population scenarios describe the forecasted disease 
burden through 2030 and three scenarios based on PITER data eval-
uate the impact of linkage to care on viraemic prevalence (Table 2).
2.2.1 | Scenarios—Italy Polaris Model
Base 2016
Represents the 2016 standard of care in Italy (treatment of pa-
tients with fibrosis stage ≥F3) maintaining the same fibrosis stage, 
Italy specific parameters in 
model Year Value (Range) Source
Total viraemic population 2015 849 000 (371 000- 1 240 000) 13
Viraemic prevalence 2015 1.39% (0.6%- 2.00%) 13
Viraemic diagnosed population 2015 357 000 (255 000- 510 000) Expert input
Annual newly linked to care for 
treatmenta
2013 30 400 Expert input
Annual number treated 2015 31 000 9
aAnnual Newly Linked to Care for Treatment encompasses those newly diagnosed each year.
TABLE  1 Key inputs of the disease 
burden model
TABLE  2  (A) Inputs by scenario, 2015- 2030. (B) Inputs of the WHO Targets scenario, 2015- 2030
A 2015 2016 2017 2018 2019 2020+
Annually treated
Base 2016 31 000 33 700 29 500 25 300 21 100 16 900
PITER (40%, 60%, 80%) — 33 700 33 700 33 700 33 700 33 700
Tx- eligible stages
Base 2016 ≥F3 ≥F3 ≥F3 ≥F3 ≥F3 ≥F3
PITER (40%, 60%, 80%) ≥F3 ≥F3 ≥F0 ≥F0 ≥F0 ≥F0
Tx- eligible ages
Base 2016 15- 64 15- 85+ 15- 85+ 15- 85+ 15- 85+ 15- 85+
PITER (40%, 60%, 80%) 15- 85+ 15- 85+ 15- 85+ 15- 85+ 15- 85+ 15- 85+
SVR
Base 2016 93% 93% 93% 93% 93% 93%
PITER (40%, 60%, 80%) — 93% 95% 98% 98% 98%
B 2015 2016 2017 2020 2022 2025+
Annually treated
WHO targets 31 000 33 700 33 700 35 700 36 700 38 000
Newly linked to carea
WHO targets 30 400 30 400 30 400 33 400 35 400 36 400
Tx- eligible stages
WHO targets ≥F3 ≥F3 ≥F0 ≥F0 ≥F0 ≥F0
Tx- eligible ages
WHO targets 15- 64 15- 85+ 15- 85+ 15- 85+ 15- 85+ 15- 85+
SVR
WHO targets 93% 93% 95% 95% 98% 98%
SVR, sustained virological response; Tx, treatment; WHO, World Health Organization.
aAnnual Newly Linked to Care for Treatment encompasses those newly diagnosed each year.
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treatment age and SVR rate assumptions through 2030. In 2016, 
30 400 patients were considered to be newly linked- to- care for 
treatment annually and 33 700 patients were treated that year. 
As no screening strategy is in place in Italy, the number of treated 
patients was expected to decrease by half by 2020 due to the 
depleting pool of eligible patients to treat.12
WHO Targets
The WHO Targets scenario identifies the expansion of diagnosis 
and treatment necessary to achieve the WHO’s 2030 targets for 
incidence, mortality and diagnosis coverage for HCV defined in the 
GHSS on Viral Hepatitis.4
2.2.2 | Scenarios—PITER adjusted model
Utilizing the PITER cohort data, three scenarios were created repre-
senting different assumptions regarding proportions of the prevalent 
population in 2015 being diagnosed and under care (40%, 60%, and 
80% linked to care). The annual number of patients treated, fibro-
sis restrictions, ages eligible for treatment and SVR were the same 
between the three scenarios (Table 2). In each PITER scenario, the 
number of patients to be treated annually following the year 2017 
was kept constant. Under the 40% linkage- to- care scenario, it was 
assumed (given expert feedback), that 40% of the prevalent popu-
lation (357 000 patients) in Italy in 2015 was diagnosed and under 
care.13 Since the exact number of patients linked- to- care remains 
unknown, the same scenario was then run under the assumption 
of 60% (510 000 patients) and 80% (680 000 patients) linkage- to- 
care. The 80% scenario was derived from from a recent study in the 
Italian general population13 and the 60% scenario was chosen as the 
midpoint.
2.3 | Sensitivity analysis
To assess the effect of uncertainties in model inputs, we used 
Crystal Ball, a Microsoft Excel (Microsoft Corporation, Redmond, 
WA, USA) add- in by Oracle (Oracle Corporation, Redwood City, CA, 
USA) to generate 95% uncertainty intervals on modelled outcomes 
through Monte Carlo simulation (1000 simulations per analysis). We 
used Beta- PERT distributions for all uncertain inputs to estimate 
the impact on total viraemic infections in 2030. The key drivers for 
prevalence uncertainties used in the sensitivity analysis are reported 
in the Results and Section 1 in Appendix S1. In addition, we consid-
ered how the variance in prevalence affects the suggested targeted 
screening strategies.
3  | RESULTS
3.1 | Base 2016 (Italy Polaris Model)
There were an estimated 849 000 (95% UI: 371 000- 1 240 000) in-
fected individuals in 2015. The forecasted impact of each scenario 
on total number of viraemic infections, HCV liver- related morbidity 
and mortality were compared through 2030 (Figures 1 and 2). Given 
the relatively large number of patients treated in Italy, total infec-
tions are expected to decline to 288 000 (95% UI: 71 880- 424 640), 
or 65%, by 2030. DC cases are forecasted to decrease 75% from 
22 900 (95% UI: 4300- 46 700) in 2015 to 6100 (95% UI: 100- 
15 300) in 2030 (Figure 2). HCC cases are also expected to decline 
from 14 000 (95% UI: 3300- 35 100) to 3800 (95% UI: 60- 12 500) by 
the same year. HCV liver- related mortality is expected to decline by 
75% from 11 300 (95% UI: 2600- 19 600) to 3100 (95% UI: 50- 7000) 
deaths by 2030.
3.2 | WHO targets (Italy Polaris Model)
In order to achieve the WHO GHSS targets, treatment was ex-
panded to 38 000 patients annually by 2025; restrictions by fibro-
sis stage were lifted, and SVR was increased incrementally over 
the next 10 years to represent the higher efficacy of treatments 
in coming years (Table 2b). Total HCV viraemic infections and HCV 
liver- related morbidity and mortality are expected to decline sub-
stantially, by 95%, 90% and 90%, respectively, by 2030 (Figure 2).
3.3 | PITER adjusted model, 40%, 60% and 80% 
linked- to- care patients
Given the 40% linkage- to- care scenario, total viraemic infections 
would decline by 60%, to 329 000 (95% UI: 199 960- 365 960) pa-
tients, by 2030. However, the eligible patients to treat would be 
depleted by 2025. Under the 60% linkage- to- care scenario, the 
patients eligible for treatment would run out in 2028. Total in-
fections were expected to decline to less than 260 000 (95% UI: 
F IGURE  1 Total viraemic infections by scenario, 2015- 2030. 
The forecasted total number of viraemic infections by Base 2016, 
PITER linkage- to- care and WHO Targets scenarios were compared. 
By 2030, total viraemic infections are expected to decline due 
to the higher treatment rate in Italy. However, the number of 
remaining infections would still remain high in each scenario. The 
WHO Scenario is forecasted to have the largest reduction on 
overall viraemic infections
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127 900- 298 100) by the same year. Under the 80% linkage- to- care 
scenario, total viraemic infections are forecasted to decline by 80%, 
from 849 000 infections to 157 000 (95% UI: 99 380- 196 980) by 
2030. The pool of eligible patients to treat is expected to be de-
pleted by 2031 (Figure 1).
In order to understand the age distribution of the eligible infected 
individuals for treatment and to suggest strategies to increase case 
finding for different linkage to care scenarios, the model estimates the 
age cohorts with the highest prevalence of asymptomatic individuals, as 
shown in Table 3. Because 30% of advanced stage liver disease (fibro-
sis stage ≥F3) patients are considered on treatment; by 2020, approx-
imately 70% of all infected, asymptomatic (F0- F3) individuals would 
be found in those born in the years 1948- 1978. According to the 40% 
linked- to- care scenario, targeted screening strategies in the 1948- 1978 
birth cohorts could be implemented to sustain the current treatment 
rate. If 60% of the infected population are linked- to- care, then screening 
fewer, younger birth cohorts, compared to the 40% linked to-care sce-
nario, specifically those born in the years 1958-1978 (Table 3) could be 
useful in finding at least 30% more of eligible infected F0- F3 individuals.
3.4 | Sensitivity analysis
The model inputs that had the largest contribution to the uncer-
tainty in the Italy Polaris and PITER adjusted models are shown in 
Figure 3A,B. For the Italy Polaris model, the anti- HCV prevalence 
in 2015 had the largest effect on the 2030 forecast of infections 
(Figure 3A). There would be approximately 535 000 remaining virae-
mic cases in 2030, as compared to 288 000, if there were 1.24 mil-
lion infections in 2015. More than 89% of the variability in the 2030 
forecasted viraemic infections could be explained by the estimated 
number of treated patients. If the eligible linked to care patients were 
to diminish and only 10 000 patients would be eligible for treatment 
moving forward (rather than the base case of 33, 700), there would 
be an estimated 260 000 viraemic cases in 2030, almost 100 000 
more than under the base assumption. The top five factors explained 
more than 98% of the variability in both models (Figure 3A,B).
In addition, we assessed how prevalence may impact the differ-
ent linkage- to- care scenarios and the related case finding strategies. 
F IGURE  2 Liver- related morbidity and mortality by scenario, 2015- 2030. The forecasted liver- related outcomes by Base 2016 and WHO 
Targets scenarios were compared. By 2030, all HCV- related outcomes are expected to decline due to the higher treatment rate in Italy. 
However, the WHO Scenario is forecasted to have the largest impact on liver- related outcomes
TABLE  3 Distribution of F0- F3 infected cases by birth year in 
the PITER and Italy Polaris models in 2020
Birth year
Proportion of F0- F3 
infected cases in 
PITER Model (%)a
Proportion of F0- F3 
infected cases in Italy 
Polaris Model (%)a
1938- 1948 28 32
1948- 1958 35 42
1958- 1968 41 26
1968- 1978 23 17
1978- 1988 10 10
1988+ 5 8
aDoes not sum to 100% due to overlapping birth cohorts.
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Given the “low” prevalence rate, the eligible patients to treat would 
be depleted sooner than under the base case (4). If prevalence was 
370 000 infections rather than the 849 000, we would expect the 
eligible patients to treat to be depleted by 2022 under the 40% 
scenario; and in 2025 under both the 60% and 80% linkage to care 
scenarios. However, if prevalence was more than a million patients, 
the eligible patient pool would be reduced by 2027 under the 40% 
linked- to- care scenario. Under the 60% and 80% scenarios, the num-
ber of treated patients (approximately 35 000) could be maintained 
annually through 2030. The prevalence did not have a significant 
impact on the identified targeted screening strategies. Assuming a 
prevalence of approximately 370 000 cases, we estimate a less than 
5% change in the distribution of F0- F3 cases by birth cohort.
4  | DISCUSSION
Italy has been considered the country with the highest HCV prev-
alence in Western Europe, with the peak prevalence in older ages 
(>70 years).14-16 However, many studies estimating HCV prevalence 
in the Italian general population were conducted more than 20 years 
ago and have shown regional variances.17 The highest prevalence 
rates have been reported in Southern Italy, though many of these 
earlier studies were conducted in smaller, more rural areas. Recent 
studies have also reported decreasing rates of HCV prevalence in 
the country.11,18,19
The limitation of HCV therapy is no longer treatment efficacy 
or adherence, but the identification of available patients to treat.20 
As with prevalence, the availability of treatment and linkage to care 
varies across the country. Though in Italy a National Hepatitis Plan 
exists, decentralized models of HCV care persist and there are no 
uniform strategies across regional networks. Only 2 (Sicily and 
Veneto) of 20 regions throughout Italy have developed adequate or-
ganizational and operational politics regarding HCV elimination.21-23 
Linkage to care is limited in that no enhanced HCV screening and di-
agnosis is implemented in the country. The number of prescribers is 
restricted only to gastrointestinal and infectious disease specialists 
whom are limited per region. It was recently estimated that there are 
1500 residents per general practitioner in Italy, often curbing the 
availability of referral and linkage to care to a specialist.13 In addition, 
no specific strategies for marginalized patients and at- risk groups are 
implemented at the national level.
A true cascade of care for HCV infection is lacking in Italy as 
the number of patients under care remains uncertain. Recent studies 
F IGURE  3 Sensitivity analysis of key drivers of uncertainty in the Italy Polaris model (A) and in the PITER adjusted model (B) in 2030 
forecasted viraemic HCV prevalence (top ten shown). The labels refer to the high and low value of the variable under consideration. For 
the Italy Polaris model, the uncertainty in new infections considered in the model had the largest effect on the 2030 forecast of prevalent 
viraemic infections. The uncertainty in transition probabilities and standardized mortality ratio due to a history of blood transfusion (see 
also Section 1 in Appendix S1) accounted for more than 98% of all explained variation in the Italy Polaris model (A). The number of treated 
patients explained the majority of the variability in the PITER model. More than 89% of the variability in the 2030 forecasted viraemic 
infections could be explained by the estimated number of treated patients. The other drivers of uncertainty in the PITER adjusted model are 
similar to Italy Polaris model (B)
TABLE  4 Year the eligible pool of patients to treat is estimated 
to be depleteda, by linkage to care scenario and prevalence range
Linkage to 
care scenario
Prevalence
Low (n) 371 000 Base (n) 849 000
High (n) 
1 240 000
40% 2022 2025 2027
60% 2025 2028 —
80% 2025 2031 —
aTo assess how the uncertainty in the prevalence estimate impacts the 
estimated number of eligible patients to treat, the linkage to care sce-
narios were run on the range of prevalence values (low: 371 000, base: 
849 000, high: 1 240 000) to assess when the treated patients may ex-
ceed eligible patients (“be depleted”). —Signifies that given the “high” 
prevalence estimate, the treated patients will not exceed eligible pa-
tients and treatment levels can be maintained through 2030.
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reported between 20% and 80% of HCV+ individuals are aware of 
their status.11,23 This uncertainty has clear implications for treat-
ment, as the population first needs to be identified in order to be 
placed in care. While the real number of linked- to- care patients in 
Italy remains unknown, the PITER cohort is considered a representa-
tive sample of linked- to- care patients in Italy.8 The PITER linkage- to- 
care scenarios are based on the characteristics of patients enrolled 
in PITER and estimates different possible proportions of the “tip of 
the iceberg.” Extrapolating the age and fibrosis stage distribution of 
current linked- to- care patients (PITER model) to the general popu-
lation in Italy (Polaris model) is useful for understanding what may 
occur in the overall infected population if current HCV trends are 
to remain at current levels. As seen in the Base 2016 Scenario, the 
WHO goal of reducing HCV liver- related deaths by 65% by 2030 is 
achievable in Italy if the treatment rate is maintained at current lev-
els. However, in the 40% and 60% linkage- to- care scenarios, given 
the same number of treated patients through 2030, the eligible pool 
of patients to be treated would run out between 2025 and 2028, 
leaving a significant proportion of infected individuals undiagnosed 
and without access to care, as is shown in Figure 1.
Considering the cohort effect of HCV infection in Italy and low 
rates of injection drug use, the younger cohorts (1988+) are those 
with the lowest prevalence of HCV infection in Italy. We did not 
consider possible screening strategies for individuals born in 1935- 
1948 as the natural depletion of the virus in those individuals was as-
sumed. This modelling estimates that more than 70% of the infected 
(F0- F3) individuals, those that are most often asymptomatic and un-
diagnosed (the underwater portion), were within the 1948 to 1978 
birth cohorts in 2020 (Table 3). This signifies a potential need to in-
crease case finding in these individuals if the treatment rate starts 
to decrease prior to the year 2025 (40% linked to care scenario). 
Similarly, though approximately 75% of individuals with chronic HCV 
in the United States are within the 1945- 1965 birth cohort, screen-
ing in this population is not systematically done and a large portion 
of infected individuals fall outside of this cohort.24 If 60% of the in-
fected population is linked- to- care then the treatment rate could be 
sustained until the year 2028. Since older individuals are more likely 
to already be linked- to- care, a specific increased case finding strat-
egy, focusing on individuals born in years 1958- 1978, could be useful 
in finding around 40% of eligible infected F0- F3 patients.
The PITER adjusted model refers to a population with a mean age 
of 59 years, which in part reflects that of populations in other parts 
of the world that have similar epidemiological characteristics (ie indi-
viduals infected previously through blood transfusion or nosocomial 
transmission with historical trends of high incidence of infection).25 
As seen in this modelling study, the rate of treatment uptake will 
decline unless screening and linking diagnosed patients to care is 
improved. In the country of Georgia, one of the nine countries on 
track to achieve the WHO Targets by 2030, the number of newly 
diagnosed patients entering the national treatment programme has 
fallen in the past year, suggesting that identification and linkage- to- 
care of HCV- infected patients in the country might be slowing.26,27 
The potential targeted screening strategies that were produced in 
this analysis are useful tools that can be used in countries with com-
parable HCV epidemiology. A similar approach can also be used for 
countries with different HCV epidemiology, in that it addresses the 
improvement of diagnosis and the linkage to care—key factors for 
achieving the elimination goals.28,29
Several limitations of the analysis exist. This analysis was not 
focused on treatment as prevention. While neither disease burden 
model dynamically considers new infections nor reinfections in the 
population, the high treatment rate in Italy coupled with the reduced 
treatment restrictions exceeds the proportion required for treat-
ment when compared to other dynamic models.30-32 In addition, 
although the PITER cohort is considered reasonably representative 
of those receiving care across the country, the PITER model uses 
a disease stage distribution based on a small proportion (9145 vs 
357 000) of diagnosed and linked- to- care patients. The true pro-
portion of the linked- to- care population in Italy is unknown. While 
rates of up to 80% have been reported,11 experts involved in the 
analysis have suggested that 40% of the total infected population is 
linked- to- care. To address this uncertainty, we presented the PITER 
analysis under three scenarios of 40%, 60% and 80% linkage- to- 
care. In addition, we evaluated the impact of this uncertainty and 
found the percent change in the linked- to- care population had a 
smaller influence on viraemic prevalence in 2030 than other factors 
(Figure 2A,B). Lastly, the variance in prevalence had limited influ-
ence on the proportion of F0- F3 patients identified and would not 
impact the screening strategies discussed.
This analysis highlights that Italy is on track to meeting the WHO 
target of 65% reduction in liver- related mortality by 2030. However, 
given the same number of annually treated patients through 2030, the 
eligible pool of patients to be treated would run out between 2025 
and 2028, leaving a significant proportion of infected individuals un-
diagnosed and without access to care. Increased case finding through 
potential targeted screening strategies are necessary to achieve the 
WHO goals. This modelling analysis is a useful tool that can be used by 
different countries to develop screening strategies for HCV elimination.
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